APA (7th ed.) Citation

Pusceddu, S., Corti, F., Prinzi, N., Nichetti, F., Ljevar, S., Busico, A., . . . Morano, F. (2023). Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: The phase Ib trial MetNET2. Journal of Hematology & Oncology, 16(1), 1. https://doi.org/10.1186/s13045-023-01510-9

Chicago Style (17th ed.) Citation

Pusceddu, Sara, et al. "Safety and Antitumor Activity of Metformin Plus Lanreotide in Patients with Advanced Gastro-intestinal or Lung Neuroendocrine Tumors: The Phase Ib Trial MetNET2." Journal of Hematology & Oncology 16, no. 1 (2023): 1. https://doi.org/10.1186/s13045-023-01510-9.

MLA (9th ed.) Citation

Pusceddu, Sara, et al. "Safety and Antitumor Activity of Metformin Plus Lanreotide in Patients with Advanced Gastro-intestinal or Lung Neuroendocrine Tumors: The Phase Ib Trial MetNET2." Journal of Hematology & Oncology, vol. 16, no. 1, 2023, p. 1, https://doi.org/10.1186/s13045-023-01510-9.